Assessing the Global Burden of IgA Nephropathy (IgAN) in Patients Receiving Hemodialysis: A Real-World Study Using DOPPS Data

This study leverages the global Dialysis Outcomes and Practice Patterns Study (DOPPS) database to generate real-world evidence on the burden of IgAN in patients who progress to kidney failure and require maintenance hemodialysis (HD). We will first aim to understand prevalence of IgAN in a global cohort of in-center HD patients. The second and third objectives aim to quantify the patient burden of IgAN using a two-step approach: first, a detailed single-arm evaluation of outcomes within the IgAN population; second, a matched comparison to the broader HD population.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

IgAN - IgA Nephropathy Autoimmune Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Glomerulonephritis Glomerulonephritis, IGA Immune System Diseases Kidney Diseases Male Urogenital Diseases Nephritis Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age ≥ 18 years at the time of enrollment
Receiving in-center HD treatment at a participating dialysis facility
Able to provide informed consent, if required by local regulations or ethics boards

Exclusion criteria

Treatment and study plan

Primary outcomes

IgAN

Time frame: 1996-2023

Sponsors and collaborators

Lead sponsor

Arbor Research Collaborative for Health

Other

Registry information

Important dates

Study start: 1996
Primary completion: 2023
Study completion: 2023
First posted: May 26, 2026
Registry last updated: May 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed